Wegovy vs Zepbound: Which GLP-1 Is Better for Weight Loss in 2026?
The two most prescribed GLP-1 weight loss drugs go head to head — clinical results, pricing, side effects, insurance, and which one is right for you.
#tirzepatide
5 articles tagged #tirzepatide.
#beginners 2#brand-name 3#compounded 1#cost 8#eli-lilly 1#foundayo 2#hims 1#injectable 5#insurance 6#medicare 3#novo-nordisk 1#oral-glp1 3#orforglipron 1#ozempic 2#ro 1#semaglutide 6#side-effects 5#tirzepatide 5#wegovy 7#wegovy-pill 1#weight-loss 12#zepbound 6
The Next Wave of Weight Loss Drugs: CagriSema, MariTide, Survodutide & What's Coming After Wegovy
Beyond Wegovy and Zepbound, a new generation of obesity drugs is racing toward FDA approval. CagriSema, MariTide (monthly injection), survodutide, and more — here's every drug in the pipeline with clinical data.
Retatrutide: The Triple-Agonist Drug That Could Redefine Weight Loss
Retatrutide achieved 28.7% weight loss in Phase 3 trials — nearly double semaglutide. Here's everything known about Eli Lilly's next-generation triple-agonist, from clinical data to expected approval timeline.
Your First Month on GLP-1 Medication: What to Expect Week by Week
Starting a GLP-1? Here's a realistic week-by-week breakdown of what happens — from the initial consultation through your first dose escalation.
GLP-1 Medications for Weight Loss: The Complete Guide for 2026
Everything you need to know about GLP-1 receptor agonists — how they work, what the clinical trials show, side effects, eligibility, and how to choose a provider.